During the study, patients will receive tranexamic acid through an intravenous (IV) line when they are admitted to the hospital and during their surgery. The study will monitor the patients’ blood levels and overall health to see how effective the treatment is in reducing blood loss. The study will also track any side effects or complications that may occur during the hospital stay and up to a year after surgery.

The study aims to provide valuable information on whether tranexamic acid can help patients with hip fractures by reducing the need for blood transfusions and improving recovery outcomes. This research could lead to better treatment options for individuals suffering from hip fractures in the future.

The purpose of the study is to determine which treatment is more effective in preventing constipation after hip surgery. Participants will be randomly assigned to receive either the bisacodyl treatment or the combination treatment. Some participants may receive a placebo. The study will monitor the need for additional medication to manage constipation over a period of 72 hours after surgery.

Throughout the study, participants will take the assigned treatment orally, and their progress will be observed to see how well the treatments work in preventing constipation. The study will help doctors understand which laxative is more effective for patients recovering from hip fracture surgery, ultimately aiming to improve patient care and comfort during recovery.

The purpose of the study is to compare the effects of these anesthetics on the heart and blood circulation. This includes monitoring blood pressure, heart rate, and oxygen levels in the blood during and after the surgery. The study aims to ensure that the anesthesia used is safe and effective for older patients undergoing hip fracture surgery. Participants will receive either levobupivacaine or bupivacaine, and some may receive a placebo. The study will observe the patients’ responses to these treatments during the surgery and for up to 48 hours afterward.

Throughout the study, researchers will closely monitor various health indicators, such as blood pressure and heart rate, to assess the safety of the anesthesia. They will also track any side effects that may occur during the surgery and in the recovery period. The study is expected to continue until the end of 2025, providing valuable information on the best anesthesia practices for older adults with hip fractures.

Participants in the study will receive either the iron treatment or a placebo. The treatment involves a single dose of ferric derisomaltose given through an injection or infusion. The study will track the recovery of movement by checking the New Mobility Score (NMS), which measures how well someone can move around. This will be assessed at different times: by phone at four weeks and in person at six and twelve weeks after the treatment.

In addition to movement recovery, the study will also look at other factors such as blood levels of hemoglobin, the need for blood transfusions, feelings of tiredness, quality of life, fear of falling, and pain related to the hip fracture. These will be measured at the start of the study and again at six and twelve weeks after the treatment. The study will also monitor any serious side effects and check on the participants’ overall health and survival up to 90 days after joining the study.

The purpose of the study is to compare the effectiveness and safety of the ESP-L block with not using any local pain relief method during hip surgery. Participants in the study will either receive the ESP-L block or no block at all. The study aims to see if the ESP-L block can reduce pain by at least one point on a pain scale two hours after surgery. Additionally, the study will look at how much pain medication is needed after surgery, the use of opioids, the ease of performing the block, any side effects, and how satisfied patients are with their pain management.

The study will follow participants through their surgery and recovery, observing their pain levels and overall experience. This research is important for understanding how to better manage pain for patients undergoing hip surgery, potentially leading to improved recovery and comfort.

The purpose of the study is to determine if giving Zoledronic Acid early, within 5 days after hip fracture surgery, is as effective as giving it later, 3 months after surgery. The study will monitor the effects of the medication on bone health over a period of 12 months. Participants will be randomly assigned to receive either the early or late treatment, and some may receive a placebo. The study will also involve monitoring various health outcomes, such as the ability to move around, the occurrence of delirium, and any changes in bone density.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their recovery from a hip fracture. The trial aims to provide valuable insights into the best timing for administering Zoledronic Acid to improve bone health and recovery in patients with hip fractures. The study is expected to continue until June 2026.